Clinical Features and Prognosis of Takayasu's Arteritis With Pulmonary Arteries Involvement

Clinical Features and Prognosis of Takayasu's Arteritis With Pulmonary Arteries Involvement

The purpose of this study is to identify the clinical features, management pattern and long-term outcomes of patients with pulmonary arteries involvement in Takayasu's arteritis (TAK-PAI).

The present study intends to conduct a prospective analysis of the clinical data in TAK patients in order to:

1. describe the clinical characteristics and current status of multimodal treatment in patients with TAK-PAI, thereby enhancing the understanding of TAK-PAI;
2. to investigate the risk factors for mortality in patients with TAK-PAI, so as to promote early intervention and reduce mortality.
3. explore factors associated with pulmonary hypertention (PH) in patients with TAK-PAI, so as to facilitate the early identification of patients who may develop PH.

Inclusion Criteria:

• Hospitalized between Jan 1, 2016 and Dec 31, 2026
• Diagnosed with TAK according to the modified Ishikawa criteria and/or 1990 American College of Rheumatology criteria and/or 2022 ACR/EULAR criteria
• Diagnosed with pulmonary artery involvement using computed tomography pulmonary angiography or transcatheter pulmonary angiography
• Patients without aortic or primary branch involvement who nonetheless exhibited both clinical features and computed tomography-confirmed evidence of pulmonary artery involvement (PAI), after exclusion of other diseases causing pulmonary artery stenosis or occlusion

Exclusion Criteria:

• Patients with PAI caused by non-TAK diseases such as other types of vasculitis, fibrosing mediastinitis, pulmonary artery sarcoma, pulmonary sarcoidosis or chronic thromboembolic pulmonary hypertension